Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark index recorded an 8.2% year-over-year increase in earnings per share (EPS), marking a significant milestone in a market
As of February 27, 2026, the global technology sector is grappling with a profound identity crisis often dubbed the "SaaS-pocalypse." While many software-as-a-service providers have seen their valuations crater under the threat of autonomous AI agents, consulting titan Accenture (NYSE:ACN) has managed to chart a different course. Following a
The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While broad market indices showed cautious optimism, the Industrial sector shattered expectations, posting a staggering 27% year-over-year earnings growth. This surge
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional "Big Pharma" mainstay, Lilly has transcended its industry peers to become a high-octane growth engine, recently flirting
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of its fourth-quarter 2025 financial results, a move that signals investor confidence in the company’s radical transformation. Once teetering on the edge of a [...]
Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative (before and after surgery) enfortumab vedotin plus pembrolizumab demonstrated a 47% reduction in the risk of tumor recurrence, progression or death compared to patients treated with standard of care neoadjuvant (before surgery) gemcitabine and cisplatin (Hazard Ratio (HR) of 0.53; 95% Confidence Interval (CI), 0.41–0.70; 1-sided p<.0001).i An estimated 79.4% of patients were event-free at two years, relative to 66.2% treated with standard of care neoadjuvant chemotherapy.i These data will be presented today in an oral session (Abstract #LBA630) and were featured in the press program at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, CA. They will also be discussed with global health authorities for potential regulatory filings.
Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the situation.
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI (encorafenib) combination as a first-line treatment for metastatic colorectal cancer (mCRC) harboring the BRAF V600E
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, struggling to find its footing in a deflationary generic drug market. However, [...]
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of $14.7 billion at the midpoint came in 2.3% above analysts’ estimates. Its non-GAAP profit of $0.57 per share was 7.4% above analysts’ consensus estimates.
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir, now marketed as Yeztugo. As of February 25, 2026, the biopharmaceutical giant has successfully transitioned from a provider of daily oral regimens
Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.
